- 米国企業
- KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.KALV
時価総額
$4.2億
PER
| 2015年 12月31日 | 2017年 4月30日 | 2018年 4月30日 | 2019年 4月30日 | 2020年 4月30日 | 2021年 4月30日 | 2022年 4月30日 | 2023年 4月30日 | |
| Revenue | - | - | 8 | 16 | 13 | - | - | - |
| Research and development | - | 13 | 18 | 35 | 40 | 41 | 70 | 80 |
| General and administrative | - | 11 | 9 | 11 | 13 | 17 | 26 | 31 |
| Total operating expenses | - | 24 | 27 | 46 | 53 | 58 | 97 | 111 |
| Operating loss | - | -22 | -19 | -30 | -41 | -58 | -97 | -111 |
| Interest income | - | 0 | 0 | 1 | 2 | 1 | 1 | 2 |
| Foreign currency exchange gain (loss) | - | 1 | -2 | 0 | -0 | 1 | -2 | 0 |
| Other income (expenses), net | - | 2 | 4 | 8 | 10 | 10 | 15 | 16 |
| Total other income | - | 4 | 3 | 9 | 11 | 12 | 14 | 18 |
| Loss before income taxes | - | - | - | -21 | -29 | -46 | -82 | -93 |
| Income tax (benefit) expense | - | - | - | 0 | -0 | - | - | - |
| Net loss | -25 | -19 | -16 | -21 | -29 | -46 | -82 | -93 |
| Foreign currency translation (loss) gain | - | -3 | 2 | -1 | 0 | 1 | -1 | -1 |
| Unrealized holding (loss) gain on marketable securities | - | - | - | 0 | 0 | -0 | -2 | 1 |
| Reclassification adjustment for realized loss (gain) on available for sale securities included in net loss | - | - | - | - | 0 | 0 | -1 | -0 |
| Total other comprehensive (loss) income: | - | - | - | - | - | 0 | -2 | 1 |
| Comprehensive loss | - | -21 | -14 | -22 | -29 | -46 | -85 | -92 |
| Net loss per share, basic | - | - | - | - | - | - | -3.36 | -3.33 |
| Net loss per share, diluted | - | - | - | - | - | - | -3.36 | -3.33 |